Cargando…
Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience
Pancreatic metastases from other neoplasms are rare. The role of surgery for this clinical entity is unclear. The aim of this study was to investigate the role of resection in patients with pancreatic secondary lesions. We observed 44 patients with pancreatic metastases from other tumors. Renal cell...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918219/ https://www.ncbi.nlm.nih.gov/pubmed/36769817 http://dx.doi.org/10.3390/jcm12031171 |
_version_ | 1784886559981436928 |
---|---|
author | Moletta, Lucia Friziero, Alberto Serafini, Simone Grillo, Valeria Pierobon, Elisa Sefora Capovilla, Giovanni Valmasoni, Michele Sperti, Cosimo |
author_facet | Moletta, Lucia Friziero, Alberto Serafini, Simone Grillo, Valeria Pierobon, Elisa Sefora Capovilla, Giovanni Valmasoni, Michele Sperti, Cosimo |
author_sort | Moletta, Lucia |
collection | PubMed |
description | Pancreatic metastases from other neoplasms are rare. The role of surgery for this clinical entity is unclear. The aim of this study was to investigate the role of resection in patients with pancreatic secondary lesions. We observed 44 patients with pancreatic metastases from other tumors. Renal cell carcinoma was the most common primary tumor (n = 19, 43.2%). Thirty-seven patients underwent surgery, and pancreatic resection with curative intent was feasible in 35 cases. Fifteen patients (43.2%) experienced major postoperative complications (Clavien-Dindo > 2), and postoperative mortality rate was 5.4%. The median overall survival and disease-free survival were 38 (range 0–186) and 11 (range 0–186) months, respectively. Overall survival and disease-free survival were significantly longer for pancreatic metastases from renal cell carcinoma when compared to other primary tumors. Multivariate analysis confirmed a pathological diagnosis of metastasis from RCC as an independent prognostic factor for overall survival (OR 2.48; 95% CI, 1.00–6.14; p = 0.05). In conclusion, radical resection of metastases to the pancreas is feasible and safe, and may confer a survival benefit for selected patients. There is a clear benefit of metastasectomy in terms of patient survival for metastases from renal cell carcinoma, while for those with other primary tumors, surgery seems to be mainly palliative. |
format | Online Article Text |
id | pubmed-9918219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99182192023-02-11 Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience Moletta, Lucia Friziero, Alberto Serafini, Simone Grillo, Valeria Pierobon, Elisa Sefora Capovilla, Giovanni Valmasoni, Michele Sperti, Cosimo J Clin Med Article Pancreatic metastases from other neoplasms are rare. The role of surgery for this clinical entity is unclear. The aim of this study was to investigate the role of resection in patients with pancreatic secondary lesions. We observed 44 patients with pancreatic metastases from other tumors. Renal cell carcinoma was the most common primary tumor (n = 19, 43.2%). Thirty-seven patients underwent surgery, and pancreatic resection with curative intent was feasible in 35 cases. Fifteen patients (43.2%) experienced major postoperative complications (Clavien-Dindo > 2), and postoperative mortality rate was 5.4%. The median overall survival and disease-free survival were 38 (range 0–186) and 11 (range 0–186) months, respectively. Overall survival and disease-free survival were significantly longer for pancreatic metastases from renal cell carcinoma when compared to other primary tumors. Multivariate analysis confirmed a pathological diagnosis of metastasis from RCC as an independent prognostic factor for overall survival (OR 2.48; 95% CI, 1.00–6.14; p = 0.05). In conclusion, radical resection of metastases to the pancreas is feasible and safe, and may confer a survival benefit for selected patients. There is a clear benefit of metastasectomy in terms of patient survival for metastases from renal cell carcinoma, while for those with other primary tumors, surgery seems to be mainly palliative. MDPI 2023-02-01 /pmc/articles/PMC9918219/ /pubmed/36769817 http://dx.doi.org/10.3390/jcm12031171 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Moletta, Lucia Friziero, Alberto Serafini, Simone Grillo, Valeria Pierobon, Elisa Sefora Capovilla, Giovanni Valmasoni, Michele Sperti, Cosimo Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience |
title | Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience |
title_full | Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience |
title_fullStr | Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience |
title_full_unstemmed | Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience |
title_short | Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience |
title_sort | safety and efficacy of surgery for metastatic tumor to the pancreas: a single-center experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918219/ https://www.ncbi.nlm.nih.gov/pubmed/36769817 http://dx.doi.org/10.3390/jcm12031171 |
work_keys_str_mv | AT molettalucia safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience AT frizieroalberto safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience AT serafinisimone safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience AT grillovaleria safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience AT pierobonelisasefora safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience AT capovillagiovanni safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience AT valmasonimichele safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience AT sperticosimo safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience |